Zuranolone Win for Postpartum Depression; Nursing Home Pills; Men & Eating Disorders
Women treated with 50 mg of zuranolone showed clinically meaningful improvements in postpartum depressive symptoms by day 15 versus placebo — meeting the primary endpoint of the phase III SKYLARK study, Sage Therapeutics and Biogen announced. The agent also met all key secondary endpoints at days 3, 28, and 45. Although antipsychotic and anxiolytic prescribing …
Zuranolone Win for Postpartum Depression; Nursing Home Pills; Men & Eating Disorders Read More »









